University: University of Edinburgh
Sector(s): Life Sciences, Healthcare & Pharmaceuticals
About Opportunity:
These genetic markers have an identified association with the individual prediction of susceptibility and severity of Paget's disease of the bone.
This technology focuses on genetic markers linked to individual prediction of susceptibility and severity of Paget's disease of the bone.
The technology consists of single nucleotide polymorphisms (SNPs) associated with prediction of Paget’s disease susceptibility and severity. Identifying individuals who carry the mutations will allow for close monitoring of disease development, and subsequent therapeutic intervention.
Similarly, predicted extent of severity will help inform on the level of patient monitoring and potential prophylactic therapy administration.
Key Benefits:
- Biomarkers shown to predict susceptibility to Paget’s disease
- Biomarkers shown to predict the likely severity of the disease
- Biomarkers identified from large scale clinical studies of 737 to 1940 patients
Applications:
- Diagnostic for identifying individuals at risk of developing Paget’s disease as well prediction of disease severity
IP Status:
This technology is available to access under the University of Edinburgh's Open Technology initiative.
Patent publication document (Reference WO2011128646A2), detailing invention, methods and results, will be provided following acceptance of the University's Open Technology standard terms and conditions.
It would help speed up access to this technology if you confirm acceptance of the published terms and conditions in the enquiry form below, indicating your proposed use for this technology.